💊Dainippon Sumitomo announces the launch of “Seebri ™ Neohaler®” for the treatment of chronic obstructive pulmonary disease (COPD) in the United States
Sanobion Pharmaceuticals, Inc. (“Sanobion” Inc.), a US subsidiary of Dainippon Sumitomo Pharma Co., Ltd., has agreed on October 19th (US time) in the United States that chronic obstructive pulmonary including chronic bronchitis and emphysema We announced the release of Seebri ™ Neohaler® (general name: Glycopyrronium bromide, hereinafter “Seiburi”), a powder formulation for inhalation used for long-term maintenance therapy of obstructive ventilatory disorder by disease (COPD) .